|
|
Article: Bristol-Myers Squibb Receives FDA Approval for TEQUIN(R) For the Short Course (5-Day) Treatment for Acute Bacterial Exacerbation Of Chronic Bronchitis (ABECB).
- Article from:
- PR Newswire
- Article date:
- November 7, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PRINCETON, N.J., Nov. 7 /PRNewswire/ --
Bristol-Myers Squibb Company (NYSE: BMY) has announced that TEQUIN(R) (gatifloxacin), a broad-spectrum fluoroquinolone antibiotic, has been approved by the U.S. Food and Drug Administration for short-course (5-day) regimen in the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB). TEQUIN(R) is already approved for ABECB, acute sinusitis and community-acquired pneumonia.
"We are very impressed that, in our research, TEQUIN(R) has been shown to be effective in treating acute exacerbation of chronic bronchitis in just five days," commented Mark H. Gotfried, M.D., FCCP, Pulmonary Associates, ...